Mendus AB (publ) (1YG.F)
- Previous Close
0.0260 - Open
0.0153 - Bid 0.0373 x --
- Ask 0.0655 x --
- Day's Range
0.0153 - 0.0248 - 52 Week Range
0.0004 - 0.1412 - Volume
19,000 - Avg. Volume
0 - Market Cap (intraday)
40.91M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
www.mendus.comRecent News: 1YG.F
Performance Overview: 1YG.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1YG.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1YG.F
Valuation Measures
Market Cap
40.91M
Enterprise Value
32.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.41
Enterprise Value/Revenue
-19.87
Enterprise Value/EBITDA
-0.35
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.19%
Return on Equity (ttm)
-16.67%
Revenue (ttm)
28.49M
Net Income Avi to Common (ttm)
-101.62M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
120.78M
Total Debt/Equity (mrq)
3.47%
Levered Free Cash Flow (ttm)
-124.09M
Company Insights: 1YG.F
1YG.F does not have Company Insights